Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Immunitas Therapeutics is a clinical-stage biotechnology company committed to discovering and developing novel, differentiated antibody-based therapeutics for cancer. Their core strategy involves reprogramming the tumor microenvironment (TME) by precisely targeting innate immune cells and specific cancer cell vulnerabilities. Leveraging a sophisticated single-cell genomics platform, Immunitas identifies and validates novel immune targets to forge impactful treatments for patients battling difficult-to-treat cancers. Their lead investigational candidate, IMT-009, an anti-CD161 antibody, is currently advancing through clinical trials for various malignancies.
The Cambridge headquarters serves as the primary center for Immunitas Therapeutics' research and development, clinical operations, corporate strategy, and administrative functions.
Located within a modern life sciences building, the headquarters likely features state-of-the-art laboratory spaces for drug discovery and translational research, alongside collaborative office environments. Its Cambridge location offers unparalleled access to a dense network of academic institutions, research hospitals, and fellow biotech companies.
As a dynamic, clinical-stage biotechnology firm, the work culture at Immunitas Therapeutics is likely characterized by a strong emphasis on scientific innovation, collaboration, agility, and a patient-centric mission. Employees are driven by the pursuit of breakthroughs in cancer treatment within a rigorous and intellectually stimulating environment.
The Cambridge headquarters is strategically significant, placing Immunitas at the heart of the biotech ecosystem. This allows for enhanced collaboration, talent acquisition, and access to cutting-edge technologies and research, all vital for advancing their therapeutic pipeline.
While Immunitas Therapeutics is headquartered in the United States, its clinical development activities, particularly for its lead programs, may involve collaborations with clinical trial sites and research institutions internationally to access diverse patient populations and expertise. The company's scientific collaborations and partnerships could also extend globally as it seeks to advance its innovative cancer therapies.
300 Third Street
Cambridge
MA
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Immunitas Therapeutics' leadership includes:
Immunitas Therapeutics has been backed by several prominent investors over the years, including:
In the past 12 months (relative to May 2024), Immunitas Therapeutics has focused on strengthening its scientific leadership. The company appointed a new Chief Scientific Officer to drive its research and discovery pipeline. No major executive departures have been publicly announced during this period.
Discover the tools Immunitas Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
While Immunitas Therapeutics does not publicly confirm its exact email format, a common structure utilized by many companies in the life sciences and biotechnology sector is [first_initial][last_name]@[companydomain.com]. Variations may exist.
[first_initial][last]@immunitastx.com
Format
jgoldberg@immunitastx.com
Example
70%
Success rate
PR Newswire • December 5, 2023
Immunitas Therapeutics shared compelling preclinical findings for IMT-009, its CD161 inhibitor, at the American Society of Hematology (ASH) Annual Meeting. The data underscored its potential as both a monotherapy and in combination treatments for hematologic malignancies....more
PR Newswire • June 7, 2023
Immunitas Therapeutics announced the appointment of Tomer Nissim Nir, Ph.D., as its new Chief Scientific Officer. Dr. Nir brings extensive experience in immunology and oncology drug discovery to spearhead the company's research initiatives....more
PR Newswire • April 11, 2023
Immunitas Therapeutics reported the dosing of the first patient in its Phase 1/2 clinical study evaluating IMT-009, a novel monoclonal antibody targeting CD161. The trial includes patients with advanced solid tumors and hematologic malignancies....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Immunitas Therapeutics, are just a search away.